Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
The efficacy and safety of sotalol were assessed by electrophysiologic testing and ambulatory recordings in 16 patients with recurrent sustained ventricular tachycardia (VT) or nonfatal cardiac arrest who were refractory to an average of 4.8 conventional antiarrhythmic agents. Twenty-four-hour ambulatory recordings were performed before and after sotalol therapy. Fourteen patients underwent baseline electrophysiologic study and sustained VT was inducible in 12. Oral sotalol (320 to 960 mg/day) completely suppressed inducible sustained VT in 7 patients (58%), with modification in 3 (25%). Ventricular premature complexes were suppressed from baseline (mean +/- standard deviation) 431 +/- 616 to 60 +/- 110/hr (p less than 0.03). After a mean follow-up of 19 +/- 7 months, 12 of 14 patients receiving sotalol treatment had successful suppression of ventricular premature complexes (60 +/- 85/hr) and remained clinically free of sustained VT, except 2 who needed additional antiarrhythmic drugs to suppress the recurrent sustained VT. One patient died suddenly after 25 months of sotalol treatment. No severe side effects were noted during sotalol therapy. This study demonstrates that sotalol is a well-tolerated, effective antiarrhythmic agent in patients at high-risk for sudden death. It appears to be beneficial in patients who did not benefit from multiple drug treatment.
Singh
S N
SN
Veterans Administration Medical Center, Cardiology Section, Washington, DC 20422.
Cohen
A
A
Chen
Y W
YW
Wish
M
M
Thoben-O'Grady
L
L
Peralba
J
J
Gottdiener
J
J
Fletcher
R D
RD
D000328:Adult; D000368:Aged; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006323:Heart Arrest / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D013015:Sotalol / Q000009:adverse effects / Q000627:therapeutic use*; D013318:Stroke Volume; D013610:Tachycardia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D013015:Sotalol